[go: up one dir, main page]

WO2008039267A3 - Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions - Google Patents

Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions Download PDF

Info

Publication number
WO2008039267A3
WO2008039267A3 PCT/US2007/016529 US2007016529W WO2008039267A3 WO 2008039267 A3 WO2008039267 A3 WO 2008039267A3 US 2007016529 W US2007016529 W US 2007016529W WO 2008039267 A3 WO2008039267 A3 WO 2008039267A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
peptide
nucleic acid
immune responses
cellular immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/016529
Other languages
French (fr)
Other versions
WO2008039267A2 (en
Inventor
Jeffrey L Alexander
Scott F Southwood
Pamuk A Bisel
Mark J Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmexa Inc
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Priority to EP07861332.0A priority Critical patent/EP2069376A4/en
Priority to AU2007300663A priority patent/AU2007300663A1/en
Priority to CA002658559A priority patent/CA2658559A1/en
Publication of WO2008039267A2 publication Critical patent/WO2008039267A2/en
Publication of WO2008039267A3 publication Critical patent/WO2008039267A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare influenza virus epitopes, and to develop epitope-based vaccines directed towards influenza virus. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of influenza virus infection.
PCT/US2007/016529 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions Ceased WO2008039267A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07861332.0A EP2069376A4 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
AU2007300663A AU2007300663A1 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
CA002658559A CA2658559A1 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83211206P 2006-07-21 2006-07-21
US60/832,112 2006-07-21

Publications (2)

Publication Number Publication Date
WO2008039267A2 WO2008039267A2 (en) 2008-04-03
WO2008039267A3 true WO2008039267A3 (en) 2008-12-31

Family

ID=39230737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016529 Ceased WO2008039267A2 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Country Status (4)

Country Link
EP (1) EP2069376A4 (en)
AU (1) AU2007300663A1 (en)
CA (1) CA2658559A1 (en)
WO (1) WO2008039267A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353157B2 (en) 2007-06-25 2016-05-31 The Administrators Of The Tulane Educational Fund Influenza inhibiting compositions and methods

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2173376T3 (en) * 2007-08-02 2015-06-29 Biondvax Pharmaceuticals Ltd Multimeric multi-epitope influenza vaccines
EP2296688A2 (en) * 2007-10-26 2011-03-23 Glykos Finland Oy Peptide vaccine for influenza virus
FI20080333A0 (en) * 2008-05-02 2008-05-02 Glykos Finland Oy Influenza virus nucleic acids and peptides
RU2528750C2 (en) * 2008-11-19 2014-09-20 Лабораторио Ави-Мекс, С.А. Де С.В. Recombinant vaccine of inactivated viral vector
US8282938B2 (en) 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
CN101792745B (en) 2009-02-04 2014-09-17 中国科学院生物物理研究所 Expression and purification of influenza virus polymerase PA N-terminal polypeptide and crystal structure thereof
CN101565455B (en) * 2009-05-25 2012-03-14 中国科学院微生物研究所 CTL epitope polypeptides of bird flu H5N1 virus and applications thereof
WO2010139047A1 (en) * 2009-06-01 2010-12-09 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
BR112012008060A2 (en) 2009-07-31 2016-11-22 Paxvax Inc adenovirus-based vectors
AU2010300623A1 (en) * 2009-09-30 2012-04-19 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
CN102153621B (en) * 2010-02-12 2014-07-02 广东省疾病预防控制中心 B-cell epitope of NA-protein for new influenza A (H1N1) and application thereof
CN102892778B (en) * 2010-02-19 2018-06-08 列日大学 For treating polynucleotides, albumen and the transgenic animals of the disease of influenza A virus induction, the modified Mx albumen of coding
WO2011138032A2 (en) * 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
AU2011305655B2 (en) 2010-09-22 2015-11-05 Alios Biopharma, Inc. Substituted nucleotide analogs
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
HK1206362A1 (en) 2012-03-21 2016-01-08 Alios Biopharma, Inc. Solid form of thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
HK1214962A1 (en) * 2013-01-10 2016-08-12 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
CN103333224B (en) * 2013-05-10 2015-03-25 中国农业科学院哈尔滨兽医研究所 Avian influenza virus NS1 protein B cell epitope polypeptide and applications thereof
JP6525214B2 (en) * 2014-06-03 2019-06-05 国立研究開発法人農業・食品産業技術総合研究機構 Antibody or antibody fragment containing the variable region thereof, antigenic polypeptide, and use thereof
US11111277B2 (en) 2016-12-28 2021-09-07 Invvax, Inc. Influenza vaccines
CN106589105B (en) * 2017-01-23 2020-09-15 中国医科大学 HLA-A2-restricted ECM1-specific CTL epitope peptides and their applications
US11517617B2 (en) 2017-09-08 2022-12-06 The University Of Melbourne Methods and compositions for preventing influenza infection
US12239699B2 (en) 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
US20230248817A1 (en) * 2020-06-19 2023-08-10 Intervet Inc. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
JP2023530135A (en) * 2020-06-19 2023-07-13 インターベット インターナショナル ベー． フェー． Swine Influenza A Virus Vaccines Containing Nucleic Acid Constructs Encoding Antigens of Specific Viral Strains
US20230270838A1 (en) * 2020-08-02 2023-08-31 Richard Ascione Vaccine compositions for influenza viruses and methods of use
JP2023541807A (en) * 2020-08-25 2023-10-04 ジェネンテック， インコーポレイテッド Assays and reagents for characterizing MHCI peptide binding
CN116410271B (en) * 2023-03-13 2024-07-19 华南农业大学 H5N1 subtype AIV MHC B1 restricted T cell epitope peptide and application thereof
CN120004989A (en) * 2025-01-16 2025-05-16 华南农业大学 H5N1 subtype AIV MHC B4 restricted T cell epitope peptides and screening methods and applications thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572620B2 (en) * 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 4 September 1998 (1998-09-04), XP008103447, Database accession no. (AF036356) *
HOELSCHER M.A. ET AL.: "Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice", THE LANCET, vol. 367, no. 9509, 11 February 2006 (2006-02-11), pages 475 - 481, XP025093947 *
MARIA GRAZIA CUSI, HUMAN VACCINES, vol. 2, no. 1, January 2006 (2006-01-01) - February 2006 (2006-02-01), pages 1 - 7, XP008103504 *
See also references of EP2069376A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353157B2 (en) 2007-06-25 2016-05-31 The Administrators Of The Tulane Educational Fund Influenza inhibiting compositions and methods

Also Published As

Publication number Publication date
AU2007300663A1 (en) 2008-04-03
EP2069376A4 (en) 2013-10-16
CA2658559A1 (en) 2008-04-03
EP2069376A2 (en) 2009-06-17
WO2008039267A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
EP1246644A4 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP1200109A4 (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2010060051A3 (en) Systems biology approach predicts the immunogenicity of vaccines
EA201071087A1 (en) MONOCLONAL ANTIBODIES, CAPABLE OF INTERACTIONING WITH A MANY SUBTIPS OF THE INFLUENZA VIRUS
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EA201270063A1 (en) PCB RECOMBINANT ANTIGENS
EA201070794A1 (en) Recombinant antigens RSV
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
PT2121011E (en) Vaccines including antigen from four strains of influenza virus
WO2008157419A3 (en) Immunogenic peptides of influenza virus
WO2007024941A3 (en) Polyvalent vaccine
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2010019262A3 (en) Polyvalent vaccine
EA200970586A1 (en) HUMAN CYTOMEGAL VIRUS ANTIBODIES (HCMV)
EA201391515A1 (en) INACTIVATED DENGE VIRUS VACCINE
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
WO2008124176A3 (en) Soluble and membrane-anchored forms of lassa virus subunit proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861332

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2658559

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007300663

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2007861332

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007861332

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007300663

Country of ref document: AU

Date of ref document: 20070723

Kind code of ref document: A